Abstract
The risk of atherosclerosis is inversely related to circulating levels of high density lipoprotein (HDL) cholesterol. Notably, in large-scale epidemiologic studies, this association is independent of plasma levels of low density lipoprotein cholesterol levels. Pharmacologic agents, such as fibrates and niacin that increase HDL cholesterol levels have been associated with decreased cardiovascular events and beneficial effects on the coronary and carotid arteries. Furthermore, there is evidence that the risk of restenosis following vascular interventions is inversely related to HDL levels. This review considers the available data from mainly murine models on potential mechanisms by which HDL may exert these anti-atherogenic effects, namely through its role in reverse cholesterol transport, its effects on endothelial cells, and its anti-inflammatory/anti-oxidant activities. In addition to discussing a role for HDL in retarding atherosclerosis progression, we will also review how HDL may play a role in promoting regression of atherosclerotic lesions.
Keywords: HDL, atherosclerosis, reverse cholesterol transport, macrophage, endothelium, coronary artery disease, inflammation, regression
Current Drug Targets
Title: Atheroprotective Effects of HDL: Beyond Reverse Cholesterol Transport
Volume: 9 Issue: 3
Author(s): Edward A. Fisher, Jonathan E. Feig and Raanan Shamir
Affiliation:
Keywords: HDL, atherosclerosis, reverse cholesterol transport, macrophage, endothelium, coronary artery disease, inflammation, regression
Abstract: The risk of atherosclerosis is inversely related to circulating levels of high density lipoprotein (HDL) cholesterol. Notably, in large-scale epidemiologic studies, this association is independent of plasma levels of low density lipoprotein cholesterol levels. Pharmacologic agents, such as fibrates and niacin that increase HDL cholesterol levels have been associated with decreased cardiovascular events and beneficial effects on the coronary and carotid arteries. Furthermore, there is evidence that the risk of restenosis following vascular interventions is inversely related to HDL levels. This review considers the available data from mainly murine models on potential mechanisms by which HDL may exert these anti-atherogenic effects, namely through its role in reverse cholesterol transport, its effects on endothelial cells, and its anti-inflammatory/anti-oxidant activities. In addition to discussing a role for HDL in retarding atherosclerosis progression, we will also review how HDL may play a role in promoting regression of atherosclerotic lesions.
Export Options
About this article
Cite this article as:
Fisher A. Edward, Feig E. Jonathan and Shamir Raanan, Atheroprotective Effects of HDL: Beyond Reverse Cholesterol Transport, Current Drug Targets 2008; 9 (3) . https://dx.doi.org/10.2174/138945008783755557
DOI https://dx.doi.org/10.2174/138945008783755557 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recent Advances in Fe-MOF Compositions for Biomedical Applications
Current Medicinal Chemistry Role of Translocator Protein in Renal Ischemia Reperfusion, Renal Preservation and Acute Kidney Injury
Current Molecular Medicine Pharmacological Aspects and Potential Use of Phloretin: A Systemic Review
Mini-Reviews in Medicinal Chemistry Gene Therapy Approaches for Cardiovascular Diseases
Current Gene Therapy Class IV Antiarrhythmic Agents: New Compounds Using an Old Strategy
Current Pharmaceutical Design Coronary Magnetic Resonance Imaging
Current Pharmaceutical Design Diabetes, the Renin-Angiotensin System and Heart Disease
Current Vascular Pharmacology The Relationship Between Hypertensive Retinopathy and Angiotensin Converting Enzyme Gene Polymorphism
Cardiovascular & Hematological Disorders-Drug Targets Editorial: Cardiovascular Disease Mortality Rates are Plateauing in Certain Age Groups and Regions. Can we Keep them Declining?
Current Vascular Pharmacology A Combination of 3D-QSAR Modeling and Molecular Docking Approach for the Discovery of Potential HIF Prolyl Hydroxylase Inhibitors
Medicinal Chemistry The Efficacy of Psychological Therapies for Specific Phobias in Adults and Some Unanswered Questions
Current Psychiatry Reviews Statins: Are They All the Same?
Current Drug Therapy Targeting Dyslipidemia in the Metabolic Syndrome: An Update
Current Vascular Pharmacology Effects of Cichorium Intybus Linn on Blood Glucose, Lipid Constituents and Selected Oxidative Stress Parameters in Streptozotocin-Induced Diabetic Rats
Cardiovascular & Hematological Disorders-Drug Targets Folate Nutrigenetics: A Convergence of Dietary Folate Metabolism, Folic Acid Supplementation, and Folate Antagonist Pharmacogenetics
Drug Metabolism Letters The Basic Biology of BACE1: A Key Therapeutic Target for Alzheimers Disease
Current Genomics Health Benefits of Ipecac and Cephaeline: their Potential in Health Promotion and Disease Prevention
Current Bioactive Compounds Recent Advances in Image-Based Stem-Cell Labeling and Tracking, and Scaffold-Based Organ Development in Cardiovascular Disease
Recent Patents on Medical Imaging Are Cerebrovascular White Matter Lesions an Early Sign of Vascular Cognitive Impairment and Vascular Dementia?
Vascular Disease Prevention (Discontinued) Nuclear Imaging of Post-infarction Inflammation in Ischemic Cardiac Diseases - New Radiotracers for Potential Clinical Applications
Current Radiopharmaceuticals